<DOC>
	<DOCNO>NCT00256360</DOCNO>
	<brief_summary>The rationale randomize phase II study investigate feasibility sequence densified FEC docetaxel base regimens patient primary operable high-risk breast cancer . Several phase III phase II clinical trial show benefit dose-dense therapy ( Q2W ) conventional treatment breast cancer , lymphoma SCLC . The aim study also demonstrate shorten treatment interval 14 day 10-11 day FEC regimen feasible compromise patient 's safety . The result randomize phase II study serve basis follow-up randomized phase III trial compare conventional versus densified sequential FEC docetaxel base regimen .</brief_summary>
	<brief_title>Trial Exploring Feasibility Densification Optimal Sequencing Postoperative Adjuvant Fluorouracil , Epirubicin Plus Cyclophosphamide ( FEC ) Docetaxel Chemotherapy Patients With High Risk Primary Operable Breast Cancer</brief_title>
	<detailed_description>Arm A : The three cycle conventional FEC follow three cycle docetaxel regimen give follow dos : Fluorouracil 500 mg/m² i.v . bolus infusion , Epirubicin 100 mg/m² 30 minute i.v . infusion Cyclophosphamide 500 mg/m² i.v . bolus infusion follow docetaxel 100 mg/m2 i.v . infusion . All drug administer intravenously Day 1 21-day cycle without support growth factor . Pegfilgrastim allow secondary prophylaxis : febrile neutropenia prolong grade IV neutropenia . In event febrile neutropenia prolong grade IV neutropenia , pegfilgrastim filgrastim give treatment , pegfilgrastim administer day 2 subsequent cycle chemotherapy . The total duration treatment 18 week . Arm B : The three cycle conventional docetaxel follow three cycle FEC regimen give follow dos : Docetaxel 100 mg/m2 i.v . infusion follow Fluorouracil 500 mg/m² i.v . bolus infusion , Epirubicin 100 mg/m² 30 minute i.v . infusion Cyclophosphamide 500 mg/m² i.v . bolus infusion . All drug administer intravenously Day 1 21-day cycle without support growth factor . Pegfilgrastim allow secondary prophylaxis : febrile neutropenia prolong grade IV neutropenia . In event febrile neutropenia prolong grade IV neutropenia , pegfilgrastim filgrastim give treatment , pegfilgrastim administer day 2 subsequent cycle chemotherapy . The total duration treatment 18 week . Arm C : The four cycle dose-dense FEC follow four cycle dose-dense docetaxel regimen give follow dos : Fluorouracil 375 mg/m² i.v . bolus infusion , Epirubicin 75 mg/m² 30 minute i.v . infusion Cyclophosphamide 375 mg/m² i.v . bolus infusion follow docetaxel 75 mg/m2 . FEC regimen administer intravenously Day 1 10-11-day cycle docetaxel give Day 1 14-day cycle . Pegfilgrastim ( Neulasta ) fix dose 6 mg ( 0.6 mL 10 mg/mL solution ) single subcutaneous injection give Day 2 study cycle . The total duration treatment 14 week . Arm D : The four cycle dose-dense docetaxel follow four cycle dose-dense FEC regimen give follow dos : Docetaxel 75 mg/m² follow Fluorouracil 375 mg/m² i.v . bolus infusion , Epirubicin 75 mg/m² 30 minute i.v . infusion Cyclophosphamide 375 mg/m² i.v . bolus infusion . Docetaxel give Day 1 14-day cycle FEC regimen administer intravenously Day 1 10-11-day cycle . Pegfilgrastim ( Neulasta ) fix dose 6 mg ( 0.6 mL 10 mg/mL solution ) single subcutaneous injection give Day 2 study cycle . The total duration treatment 14 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically proven early breast cancer require adjuvant chemotherapy ( lymph node positive feature high risk accord StGallen criterion ) Margins resection histologically free invasive carcinoma ductal carcinoma situ . Radiotherapy perform accord center 's policy always follow completion adjuvant chemotherapy Performance status 0 1 ECOG scale ( Appendix A ) The determination ER PgR mandatory ( immunohistochemical method require ; ER and/or PgR positivity define &gt; 1 % positive cell ) . Also determination Her2neu mandatory , either immunohistochemistry FISH Age &gt; 18 year age &lt; 70 year ( upper age limit base lack safety data population ) . Normal cardiac function ( assessment LVEF MUGA scan echocardiography lower limit normal institution ) . Adequate organ function ( define neutrophils &gt; 1.5 x109/L , Platelets &gt; 100 x 109/L , Hemoglobin &gt; 10 g/dl , total bilirubin &gt; 1 UNL , ASAT ( SGOT ) ALAT ( SGPT ) &gt; 1.5 UNL , alkaline phosphatase &gt; 2.5 UNL , creatinine &gt; 1.5 mg/dl ( 150 µmol/L ) Complete stag workup within 2 month prior registration . All patient bilateral mammography , chest Xray ( PA lateral ) and/or CTscan , abdominal ultrasound and/or CT scan , bone scan . In case positive bone scan suspicious metastasis , bone Xray ( bone CTscan spinal hot spot ) mandatory rule possibility metastatic disease . Other test may perform clinically indicate . Negative pregnancy test ( urine serum ) within 7 day prior registration woman childbearing potential . Patients childbearing potential must implement adequate nonhormonal measure avoid pregnancy study treatment ( chemotherapy , radiotherapy endocrine therapy ) . No pregnant lactating patient allow . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Before patient registration/randomization , write informed consent must give accord ICH/GCP , national/local regulation . Exclusion criterion : Metastatic disease ( M1 ) inoperable residual axillary disease Prior systemic anticancer therapy breast cancer ( chemotherapy , hormone therapy immunotherapy ) Prior radiation therapy breast cancer . Preexisting motor sensory neurotoxicity severity &gt; grade 2 NCI criterion . Pregnant lactating patient Other serious illness medical condition : Congestive heart failure unstable angina pectoris , previous history myocardial infarction within 1 year study entry , uncontrolled hypertension highrisk uncontrolled arrhythmias . History significant neurological psychiatric disorder would prohibit understanding give informed consent . Active uncontrolled infection Active peptic ulcer , unstable diabetes mellitus . Past current history neoplasm except curatively treat basal cell skin cancer situ carcinoma cervix . Chronic treatment steroid unless initiate &gt; 6 month prior study entry low dose ( &lt; 20 mg methylprednisolone equivalent ) Concurrent treatment hormonal replacement therapy : treatment stop least 15 day study entry . Concurrent treatment experimental drug . Participation another clinical trial investigational market drug within 30 day prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>adjuvant</keyword>
	<keyword>dose dense</keyword>
	<keyword>docetaxel</keyword>
	<keyword>pegfilgrastim</keyword>
</DOC>